Tinnitus is the medical term for hearing a sound that does not come from an outside source. It is often described as ringing in the ears, but it may also sound like buzzing, humming, hissing, clicking, roaring, or whistling. It can affect one ear, both ears, or feel as though the sound is coming from inside the head.
Possible causes include hearing loss, loud-noise exposure, earwax buildup, ear infections, certain medications, or conditions affecting the inner ear. Tinnitus may be temporary, come and go, or continue for a long time.
Current research does not show that retatrutide commonly causes tinnitus or directly damages hearing. Tinnitus has not been reported in published retatrutide studies so far. However, the drug is still investigational, and its complete safety profile has not been finalized.
Quick answer
There is currently no solid evidence that retatrutide causes tinnitus or hearing loss. Tinnitus was not identified among the commonly reported side effects in retatrutide clinical trials.
If ringing begins with sudden hearing loss, severe dizziness, or symptoms affecting only one ear, seek prompt medical evaluation. Retatrutide also remains unapproved in the United States as of this writing, so any product sold outside an authorized clinical trial carries additional safety and quality concerns.
What is retatrutide?
Retatrutide is an investigational, once-weekly injection being developed by Eli Lilly for obesity, type 2 diabetes, and related conditions. It activates three hormone receptors called GLP-1, GIP, and glucagon receptors.
The GLP-1 and GIP portions affect appetite, digestion, and blood sugar. The glucagon portion adds another effect on energy use and metabolism. This three-receptor design is why retatrutide is sometimes described as a triple hormone receptor agonist.
In a 2023 Phase 2 obesity trial involving 338 adults, participants receiving the highest dose lost an average of 24.2% of their starting weight over 48 weeks. The most common adverse events were digestive, and higher doses produced temporary increases in heart rate.
More recent Phase 3 results have reported even greater average weight loss. In May 2026, Lilly announced that 2,339 participants had been randomized in TRIUMPH-1. Participants receiving 12 mg lost an average of 28.3% of their starting weight at 80 weeks. These were public topline results, and the complete study findings had not yet appeared in a peer-reviewed journal at the time of writing.
Is retatrutide FDA-approved?
No. As of July 18, 2026, retatrutide is still investigational and does not have FDA approval for weight loss, diabetes, or any other condition.
Lilly states that authentic retatrutide is legally available only to people enrolled in its clinical trials. The FDA also says that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. The FDA’s warning about unapproved GLP-1 products specifically mentions retatrutide.
Any website offering “prescription retatrutide,” “compounded retatrutide,” or “research retatrutide” directly to consumers is not selling an FDA-approved medication. The vial could contain the wrong concentration, an undeclared ingredient, contamination, or no retatrutide at all.
That uncertainty is especially relevant when someone develops tinnitus. A symptom cannot confidently be attributed to retatrutide if the product’s contents and dose are unknown.
Can retatrutide cause tinnitus?
Retatrutide trials have not identified tinnitus or hearing loss among the commonly reported adverse events.
In TRIUMPH-1, the most common events at the 12 mg dose included:
-
- nausea in 42.4% of participants,
- dysesthesia occurred in 12.5%,
- diarrhea in 32%,
- constipation in 26.1%, and
- vomiting in 25.3%.
In TRIUMPH-4, retatrutide’s most common side effects were nausea, diarrhea, constipation, vomiting, and reduced appetite, especially at the 9 mg and 12 mg doses. Dysesthesia, or unusual skin sensations, occurred in 8.8% of people taking 9 mg and 20.9% taking 12 mg, compared with 0.7% on placebo, but these cases were usually mild.
The available evidence does not point toward tinnitus as a frequent retatrutide reaction. Future FDA reviews will provide a more detailed account of uncommon adverse events.
What retatrutide users said about tinnitus
The Reddit post came from someone who already had mild tinnitus before starting retatrutide. Normally, the ringing was quiet enough to notice only in complete silence. After using retatrutide, however, it became loud enough to interfere even while watching television.
Did anyone who had worsening tinnitus from reta find a way to stop it?
byu/Impossible_Pen4714 inRetatrutide
A few commenters said they had also noticed new or louder tinnitus while using retatrutide. One person said they developed tinnitus after starting it and had not previously considered the medication as a possible cause. Another reported severe tinnitus after about six months of use, although they were unsure whether retatrutide was responsible.
One commenter said their tinnitus had become louder, but they had also been spending more time around loud music and amplifiers. That made it difficult to know whether the medication, noise exposure, or both were contributing.
Another post came from someone who had lived with tinnitus for about 20 years. They said the ringing became much louder immediately after their first 0.5 mg dose of retatrutide. They also developed pressure in their ears or head and severe dry eyes.
A few users said they had also experienced tinnitus or louder ear ringing while using retatrutide or other GLP-1 medications. One person reported developing tinnitus at 4 mg, although it later disappeared while they continued treatment. Another said semaglutide seemed to worsen their tinnitus, while tirzepatide had not caused the same problem during the first few weeks.
Can retatrutide damage your hearing?
There is no clinical proof that retatrutide damages the inner ear, hearing nerve, or the part of the ear that processes sound. Researchers have also not established retatrutide as an ototoxic drug.
Ototoxic drugs are medications known to harm hearing or balance. Examples include certain chemotherapy drugs, some strong antibiotics, loop diuretics, and high doses of certain pain relievers.
Still, research on retatrutide and hearing is limited. To know whether it can cause subtle hearing changes, researchers would need to test people’s hearing before and during treatment, track tinnitus symptoms, and follow patients for a longer period.
Can GLP-1 medications cause tinnitus or damage your hearing?
Research on GLP-1 drugs has also shown mixed results. Some databases show more ear-related reports or diagnoses among users, while randomized trials have not found a consistent hearing risk across the drug class.
A 2025 study reviewed 9,746 reports of ear, nose, and throat problems linked to several GLP-1 medications, including exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide. Liraglutide showed a possible reporting link with tinnitus. However, the study did not find strong evidence that tinnitus was a common effect across the entire GLP-1 drug class.
Another 2025 analysis reviewed 29 randomized clinical trials involving nearly 146,000 people to see whether GLP-1 drugs or SGLT2 inhibitors were linked to hearing loss. Most of the medications studied did not show a higher risk of hearing loss. However, two GLP-1 drugs, lixisenatide and high-dose efpeglenatide, were linked to more hearing-loss events than the comparison treatments. Lixisenatide showed the strongest signal.
Both drugs belong to a subgroup of GLP-1 medications called exendin-4 derivatives. The researchers said doctors may want to be more cautious when prescribing these drugs to people who already have a higher risk of hearing problems. But the findings do not show that all GLP-1 medications cause hearing loss.
In 2026, researchers compared 342,046 people who used GLP-1 medications with the same number of similar people who did not use them. In total, the study included more than 684,000 participants.
During follow-up, GLP-1 users were diagnosed more often with balance disorders, dizziness, and hearing problems.
-
- There were 4,407 vestibular disorder cases among GLP-1 users, compared with 3,946 among nonusers.
- Dizziness occurred in 32,545 GLP-1 users and 29,931 nonusers.
- Hearing impairment occurred in 9,522 and 7,898 people, respectively.
The differences were statistically significant, but the study still does not prove that GLP-1 medications directly caused these problems. Other health differences or unmeasured factors may have affected the results.
The American Academy of Otolaryngology–Head and Neck Surgery said the evidence linking approved GLP-1 drugs to tinnitus and hearing loss is still weak. These hearing problems are not considered well-established side effects, and the results have not been consistent across all GLP-1 medications.
Possible causes of tinnitus during retatrutide treatment
Ear symptoms during treatment may develop through indirect pathways or for reasons unrelated to retatrutide.
1. Rapid weight loss and the Eustachian tube
Weight loss itself may also cause certain ear symptoms. One possible condition is a patulous Eustachian tube.
The Eustachian tube runs between the middle ear and the back of the nose. It normally opens and closes to regulate ear pressure. Fatty tissue helps support the tube. But after a major weight loss, the tube may stay abnormally open in some people. This condition is called patulous Eustachian tube dysfunction.
Possible symptoms include:
-
- Ear fullness or pressure
- Muffled or distorted hearing
- Hearing your own voice unusually loudly
- Hearing your breathing inside your ear
- Echoing or fluttering sensations
- Tinnitus in some cases
Doctors believe rapid or significant weight loss may reduce the fatty tissue that normally helps the Eustachian tube close. Two cases have been reported after GLP-1 use, but researchers do not yet know how often this condition occurs.
An FDA adverse-event database analysis found that ear-related reports made up about 0.99% of the cases reviewed, with decreased hearing and vertigo reported most often. However, these reports cannot prove that GLP-1 medications caused the symptoms.
Interestingly, some early research suggests GLP-1 drugs might also have protective effects on the inner ear. In a chinchilla study, liraglutide reduced hearing damage after a loud blast injury.
2. Low blood sugar
Low blood sugar may temporarily trigger or worsen tinnitus in some people. The inner ear, specifically the cochlea, has no energy reserves of its own and relies entirely on a continuous, steady supply of oxygen and glucose from the bloodstream to function properly.
When blood sugar drops suddenly, the cells in the cochlea and the hearing pathways may not receive enough energy. This could briefly disturb how sound signals are processed and cause ringing, buzzing, or other unusual sounds.
3. Reduced food intake and nutritional problems
Retatrutide can greatly reduce appetite and may contribute to vitamin and nutritional deficiencies over time.
Certain nutritional deficiencies may trigger or worsen tinnitus:
-
- Iron deficiency (anemia): With fewer healthy red blood cells, less oxygen reaches body tissues. The heart may pump faster, and blood may flow more forcefully, which can sometimes produce a pulsing or whooshing sound that matches the heartbeat. Anemia is a recognized possible cause of pulsatile tinnitus.
-
- Vitamin B12 deficiency: B12 helps keep nerve cells and red blood cells healthy. A severe or prolonged deficiency can damage the nervous system, so researchers suspect it could affect the hearing nerve or the brain pathways that process sound.
-
- Zinc deficiency: Zinc is involved in nerve communication and normal inner-ear function. Some studies have found that people with low zinc levels report more severe tinnitus.
-
- Other deficiencies: Low magnesium or vitamin D levels have been linked with tinnitus in some small studies, but researchers do not yet know whether correcting these levels consistently improves symptoms.
4. Another medication or health condition
Tinnitus is common in the general population. The National Institute on Deafness and Other Communication Disorders estimates that 10% to 25% of adults experience it.
Several common medications can cause or worsen tinnitus. Examples include high doses of aspirin, ibuprofen or naproxen, certain antibiotics, loop diuretics, some cancer drugs, antimalarial drugs, and some antidepressants.
Other possible causes include:
-
- Loud concerts, machinery, firearms, or headphones
- Age-related hearing loss
- Earwax blockage
- Ear infection or fluid
- Jaw clenching or teeth grinding
- Migraine
- Ménière’s disease
- High blood pressure
- Thyroid disease
- Anemia
- Head or neck injury
- A benign tumor affecting the hearing nerve
It may help to review all your medications with your doctor and have your hearing checked to look for other possible causes.
How can you tell whether tinnitus is related to retatrutide?
Timing, symptom pattern, dose history, hearing-test results, and other possible causes can help assess the connection.
Write down the following information before an appointment:
-
- The date and approximate time the tinnitus began
- Whether it started after the first injection or a dose increase
- How long after the injection it appeared
- Whether the sound is in one ear, both ears, or inside the head
- Whether it rings, buzzes, hisses, roars, clicks, or pulses
- Whether the pulse matches your heartbeat
- Any muffled hearing, ear pressure, dizziness, or balance problems
- Recent weight loss and how quickly it occurred
- Vomiting, diarrhea, poor fluid intake, or very low food intake
- Blood sugar readings if you have diabetes
- Recent loud-noise exposure
- Every prescription drug, over-the-counter medication, and supplement used
- Where the retatrutide product came from
If the symptom keeps appearing after each injection, the medication may be involved. Still, that pattern alone cannot confirm it. Do not take another dose just to test whether the symptom comes back.
What should you do if tinnitus starts while using retatrutide?
Follow these steps:
When should you call a doctor?
Sudden hearing loss with tinnitus needs immediate medical attention. New one-sided, pulsatile, or persistent tinnitus should also be evaluated, although it may not require an emergency room when no other warning signs are present.
| Symptom pattern | Suggested response |
| Sudden hearing loss over hours or a few days, with or without tinnitus | Seek same-day emergency or urgent ENT evaluation |
| Tinnitus with facial drooping, weakness, confusion, severe headache, or trouble speaking | Call emergency services |
| Pulsing in time with the heartbeat, especially with vision changes or severe headache | Seek urgent medical assessment |
| Severe spinning, inability to walk, repeated vomiting, or fainting | Seek urgent care |
| Ringing in one ear that persists or is accompanied by unequal hearing | Arrange prompt medical and hearing evaluation |
| Ear pain, drainage, fever, or marked fullness | Schedule an examination for infection or blockage |
| Mild ringing in both ears without hearing loss or other symptoms | Monitor briefly and arrange care if it persists, worsens, or becomes bothersome |
The NIDCD considers sudden sensorineural hearing loss a medical emergency. Although about half of patients recover some hearing on their own, delaying diagnosis and treatment can reduce treatment effectiveness. NIDCD guidance on sudden hearing loss recommends immediate evaluation.
How will a doctor evaluate tinnitus?
The evaluation usually starts with a medication review and an examination of the ears. A clinician will look for earwax, infection, fluid, eardrum problems, and signs of Eustachian tube dysfunction.
An audiologist may perform:
-
- Pure-tone testing to measure the quietest sounds you can hear
- Speech testing to measure how clearly you understand words
- Tympanometry to examine middle-ear pressure and eardrum movement
- Tests comparing hearing between the ears
- Tinnitus pitch or loudness matching when useful
An ENT may order imaging when tinnitus pulses with the heartbeat, occurs only on one side, or appears with unequal hearing or neurologic symptoms. Blood work may be considered when anemia, thyroid disease, a nutritional deficiency, abnormal glucose, or dehydration is possible.
Can tinnitus be treated?
Possible approaches include:
Should you stop retatrutide if your ears start ringing?
Do not make an unsupervised dose change if you are receiving retatrutide in a legitimate clinical trial. Contact the study team promptly so investigators can evaluate the symptom and decide whether treatment should be paused, reduced, or discontinued.
If the product came from an online peptide seller, wellness business, or supposed compounding source, contact a licensed clinician before taking another dose. The FDA says retatrutide cannot legally be used in compounding, and products sold outside clinical trials have not undergone FDA review for identity, strength, sterility, or effectiveness.
Frequently Asked Questions
Articles you may also be interested in
